Aethlon Medical, Inc. announced on May 14, 2025, the publication of a preclinical ex vivo study in bioRxiv, demonstrating the Hemopurifier's ability to remove platelet-derived extracellular vesicles (PD-EVs) from plasma. The study, published on May 12, 2025, showed a 98.5% removal of CD41-positive PD-EVs from healthy human plasma in a simulated 4-hour treatment session.
PD-EVs are the most numerous EV population in the body and are implicated in a wide range of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, and acute and Long COVID. The high removal rate reinforces the scientific basis for Aethlon's ongoing oncology clinical trial in Australia.
These findings suggest a broad therapeutic strategy for the Hemopurifier across multiple indications where excessive levels of PD-EVs play a role. The company plans to submit the manuscript to a peer-reviewed medical journal and further investigate PD-EV removal in plasma samples from various diseases of interest.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.